#Amgen

Last 7 Days 📈 Bullish 📈1

Last 30 Days 📈 Bullish 📈1

Release 📈 Stocks

Amgen Repatha Reduces Heart Attack Risk by 20% in Real-World Study

November 5, 2026 (5 days ago)

A large-scale real-world study shows Amgen's Repatha outperforms ezetimibe by reducing heart attack risk by 20%, offering new clinical data to guide…

AMGN

🌍 US Read More →

News 📈 Stocks

June 26, 2026 (137 days ago)

Amgen’s Tavneos faces EU withdrawal after regulators question clinical data integrity, threatening a growth driver and pressuring AMGN shares.

AMGN

🌍 EU Read More →